The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1501381
This article is part of the Research Topic Clinical Pharmacist Service Promotes the Improvement of Medical Quality Volume II View all 22 articles
Effects of Pharmacogenomics-guided Treatment on Medication Adherence and the Rate of Antidepressant Switching in Major Depressive Disorder
Provisionally accepted- 1 Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
- 2 Department of The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, shijiazhuang, China
- 3 Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
- 4 Key Laboratory for Neuroimmunological Regulation and Mental Health of Hebei Province, shijiazhuang, China
- 5 harmacy Department, The First Hospital of Hebei Medical University, shijiazhuang, China
- 6 School of Pharmacy, Hebei Medical University,, shijiazhuang, China
- 7 The First Hospital of Hebei Medical University, shijiazhuang, China
Background:In the treatment of depression, medication plays a crucial role.However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system. Objectives:Our objective was to examine the impact of pharmacogenomic testing on medication adherence and antidepressant switching rates among individuals diagnosed with depression. Methods:This retrospective cohort study encompassed patients diagnosed with depression who were admitted to the First Hospital of Hebei Medical University between April 2022 and September 2023. Patients were categorized into a pharmacogenomics-guided treatment (PGxT)group and a treatment as usual (TAU) group based on whether pharmacogenetic testing was conducted. The primary outcome measures included the proportion of patients exhibiting medication adherence greater than 80% at three and six months post-discharge, as well as the proportion of patients experiencing changes in their prescribed medication types. Results:A total of 310 patients in the PGxT group and TAU group were obtained through propensity score matching. Among the 620 patients in both groups, 57.42% demonstrated good adherence (≥ 80%) at three months; this percentage dropped to 31.45% at six months. At three months of observation, the percentages of patients demonstrating good adherence were significantly different between the groups (64.52% in the PGxT group vs. 50.32% in the TAU group; p < 0.001). The difference was also significant after six months (38.06% in the PGxT group vs. 24.84% in the TAU group; p < 0.001). Furthermore, patients receiving PGxT (20.64%) exhibited a lower rate of antidepressant conversion compared to those receiving TAU (31.29%). Conclusion:The findings of this study indicate that pharmacogenomics testing positively influences treatment adherence and may decrease the need to switch medications among patients with depression.
Keywords: pharmacogenomics, adherence, switching, Depression, antidepressant
Received: 25 Sep 2024; Accepted: 15 Nov 2024.
Copyright: © 2024 Chen, Lun, Yu, Zhao, Su, Zhao, Yan, Wang, Fu, An, Duan, Yan, Li, Li, Liu, Geng, Wang, Zhao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Lun, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Xiaochuan Zhao, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Shi Su, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Yuhang Yan, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Jiaqi Wang, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Ran Fu, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Feiyue An, harmacy Department, The First Hospital of Hebei Medical University, shijiazhuang, China
Liguang Duan, harmacy Department, The First Hospital of Hebei Medical University, shijiazhuang, China
Leting Yan, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Ruxing Li, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Jinxiao Li, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Ziyu Liu, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Xiaoying Geng, School of Pharmacy, Hebei Medical University,, shijiazhuang, China
Jincheng Wang, Mental Health Center, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Yuanyuan Zhao, The First Hospital of Hebei Medical University, shijiazhuang, China
Chunhua Zhou, Department of Clinical Pharmacy, The First hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.